Request Demo
Last update 28 Feb 2025
CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Last update 28 Feb 2025
Overview
Basic Info
Drug Type CAR-NK |
Synonyms CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells |
Target |
Mechanism CD70 inhibitors(CD70 antigen inhibitors), IL15R agonists(Interleukin-15 receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)NCT05703854
Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
NCT05092451
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
100 Clinical Results associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Translational Medicine associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Patents (Medical) associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Deals associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Renal Cell Carcinoma | Phase 2 | US | 29 Mar 2023 | |
| Mesothelioma | Phase 2 | US | 29 Mar 2023 | |
| Metastatic osteosarcoma | Phase 2 | US | 29 Mar 2023 | |
| Acute Myeloid Leukemia | Phase 2 | US | 01 Nov 2022 | |
| Blast Phase Chronic Granulocytic Leukemia | Phase 2 | US | 01 Nov 2022 | |
| Germ Cell and Embryonal Neoplasms | Phase 2 | US | 01 Nov 2022 | |
| Hodgkin's Lymphoma | Phase 2 | US | 01 Nov 2022 | |
| Myelodysplastic Syndromes | Phase 2 | US | 01 Nov 2022 | |
| Plasma Cell Leukemia | Phase 2 | US | 01 Nov 2022 | |
| T-Cell Lymphoma | Phase 2 | US | 01 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free